HRA Pharma is a European leader in emergency contraception, after developing the first levonorgestrel-based emergency contraceptive in 1999 and introducing the new generation product ellaOne, an ulipristal acetate-based emergency contraceptive, now available in over 80 countries worldwide. HRA Pharma later developed Esmya, a breakthrough innovation in non-surgical treatment of uterine fibroids.
HRA Pharma also holds a strong and successful global franchise in the therapeutic area of rare endocrine diseases, focused in particular on the Cushing syndrome. Each year, HRA invests a significant share of its revenue in R&D and has a rich and innovative development pipeline in its core therapeutic areas.
HRA Pharma has set up a commercial infrastructure across eleven European countries through seven subsidiaries and has built a global distribution network for its products across 80 countries.